-
Who we are
Who we are
Novavax is a global biotechnology company with a proven vaccine technology. We are focused on developing our R&D assets and establishing partnerships to leverage the value of our technology to help protect health.
Discover our scienceLearn about our validated protein-based nanoparticle and Matrix-M™ adjuvant technology.
-
What we do
What we do
Novavax is focused on using our proven vaccine technology to help protect health through the development of our R&D assets and establishing partnerships
Latest UpdatesStay current with Novavax news as we make progress in discovering and developing innovative vaccines to help protect against serious infectious diseases.
-
Blog
Blog
Novavax is committed to accelerating the development of new and promising vaccines and sharing information based on years of study and experience.
Investor Hub
Novavax is a global biotechnology company with a proven vaccine technology. We are focused on developing our R&D assets and establishing partnerships to leverage the value of our technology to help protect health.
Latest quarterly earnings
Latest investor presentation
Latest clinical presentation
Annual report
Latest publications
Pipeline
NASDAQ:NVAX
Reports & financials by fiscal year
Fiscal year | Quarterly earnings | Annual reports & proxy statements | Quarterly filings |
---|---|---|---|
2024 | Quarterly earnings | Annual reports & proxy statements | Quarterly filings |
2023 | Quarterly earnings | Annual reports & proxy statements | Quarterly filings |
2022 | Quarterly earnings | Annual reports & proxy statements | Quarterly filings |
2021 | Quarterly earnings | Annual reports & proxy statements | Quarterly filings |
2020 | Quarterly earnings | Annual reports & proxy statements | Quarterly filings |
2019 | Quarterly earnings | Annual reports & proxy statements | Quarterly filings |
2018 | Quarterly earnings | Annual reports & proxy statements | Quarterly filings |
Get notifications for investor updates
Sign up for notifications from Novavax including upcoming events, webcasts, research updates, daily stock closings, SEC filings and more.
Shareholders seeking information can contact investor relations at (240) 268-2022 or contact us.
Novavax corporate policy prohibits any employees, other than designated spokespersons, from communicating with its investors.